Abstract
The major reasons for developing human monoclonal antibodies were to be able to efficiently manipulate their effector functions while avoiding immunogenicity seen with rodent antibodies. Those effector functions involve interactions with the complement system and naturally occurring Fc receptors on diverse blood white cells. Antibody immunogenicity results from the degree to which the host immune system can recognize and react to these therapeutic agents. Thus far, there is still no generally applicable technology guaranteed to render therapeutic antibodies antigenically silent. This is not to say that the task is impossible, but rather that we need to train the immune system to help us. This can be achieved if we take advantage of natural mechanisms by which an individual can be rendered tolerant of “foreign” antigens, and as a corollary minimize the potential immunogenicity of any contaminating protein aggregates, or “aggregates” arising from antibodies complexing with their antigen. I here summarize our efforts to engineer antibodies to harness optimal effector functions, while also minimizing their immunogenicity. Potential avenues to achieve the latte are predicted from classical work showing that monomeric “foreign” immunoglobulins are good tolerogens, while aggregates of immunoglobulins ate intrinsically immunogenic. Consequently, I argue that one solution to the immunogenicity problem lies in ensuring a temporal quantitative advantage of tolerogenic non-cell-bound monomer over the cell-binding immunogenic form.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Kohler G, Milstein C (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256(5517):495–497
Steinitz M et al (1977) EB virus-induced B lymphocyte cell lines producing specific antibody. Nature 269(5627):420–422
Bruggemann M et al (1989) The immunogenicity of chimeric antibodies. J Exp Med 170(6):2153–2157
Jones PT et al (1986) Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 321(6069):522–525
Riechmann L et al (1988) Reshaping human antibodies for therapy. Nature 332(6162):323–327
Lonberg N (2005) Human antibodies from transgenic animals. Nat Biotechnol 23(9):1117–1125
Winter G et al (1994) Making antibodies by phage display technology. Annu Rev Immunol 12:433–455
Bruggemann M et al (1989) A repertoire of monoclonal antibodies with human heavy chains from transgenic mice. Proc Natl Acad Sci U S A 86(17):6709–6713
Clark M (2000) Antibody humanization: a case of the ‘Emperor’s new clothes’? Immunol Today 21(8):397–402
Chiller JM, Habicht GS, Weigle WO (1970) Cellular sites of immunologic unresponsiveness. Proc Natl Acad Sci U S A 65(3):551–556
Cobbold SP et al (1984) Therapy with monoclonal antibodies by elimination of T-cell subsets in vivo. Nature 312(5994):548–551
Neuberger MS, Williams GT, Fox RO (1984) Recombinant antibodies possessing novel effector functions. Nature 312(5995):604–608
Bruggemann M et al (1989) A matched set of rat/mouse chimeric antibodies. Identification and biological properties of rat H chain constant regions mu, gamma 1, gamma 2a, gamma 2b, gamma 2c, epsilon, and alpha. J Immunol 142(9):3145–3150
Morrison SL et al (1984) Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc Natl Acad Sci U S A 81(21):6851–6855
Bruggemann M et al (1987) Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies. J Exp Med 166(5):1351–1361
Bindon CI et al (1988) Human monoclonal IgG isotypes differ in complement activating function at the level of C4 as well as C1q. J Exp Med 168(1):127–142
Bolt S et al (1993) The generation of a humanized, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties. Eur J Immunol 23(2):403–411
Kuhn C et al (2011) Human CD3 transgenic mice: preclinical testing of antibodies promoting immune tolerance. Sci Transl Med 3(68):68ra10
Friend PJ et al (1999) Phase I study of an engineered aglycosylated humanized CD3 antibody in renal transplant rejection. Transplantation 68(11):1632–1637
Keymeulen B et al (2005) Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 352(25):2598–2608
Routledge EG et al (1991) A humanized monovalent CD3 antibody which can activate homologous complement. Eur J Immunol 21(11):2717–2725
Beers SA, Glennie MJ, White AL (2016) Influence of immunoglobulin isotype on therapeutic antibody function. Blood 127(9):1097–1101
Benjamin RJ et al (1986) Tolerance to rat monoclonal antibodies. Implications for serotherapy. J Exp Med 163(6):1539–1552
Waldmann H, Adams E, Cobbold S (2008) Reprogramming the immune system: co-receptor blockade as a paradigm for harnessing tolerance mechanisms. Immunol Rev 223:361–370
Rebello PR et al (1999) Anti-globulin responses to rat and humanized CAMPATH-1 monoclonal antibody used to treat transplant rejection. Transplantation 68(9):1417–1420
Eichmann K (1973) Idiotype expression and the inheritance of mouse antibody clones. J Exp Med 137(3):603–621
Somerfield J et al (2010) A novel strategy to reduce the immunogenicity of biological therapies. J Immunol 185(1):763–768
Feldmann M, Maini RN (2001) Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol 19:163–196
Jefferis R (2011) Aggregation, immune complexes and immunogenicity. MAbs 3(6):503–504
Joubert MK et al (2012) Highly aggregated antibody therapeutics can enhance the in vitro innate and late-stage T-cell immune responses. J Biol Chem 287(30):25266–25279
Moussa EM et al (2016) Immunogenicity of therapeutic protein aggregates. J Pharm Sci 105(2):417–430
Sauerborn M et al (2010) Immunological mechanism underlying the immune response to recombinant human protein therapeutics. Trends Pharmacol Sci 31(2):53–59
St Clair JB et al (2017) Immunogenicity of Isogenic IgG in Aggregates and Immune Complexes. PLoS One 12(1):e0170556
De Groot AS, Scott DW (2007) Immunogenicity of protein therapeutics. Trends Immunol 28(11):482–490
Harding FA et al (2010) The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions. MAbs 2(3):256–265
Griswold KE, Bailey-Kellogg C (2016) Design and engineering of deimmunized biotherapeutics. Curr Opin Struct Biol 39:79–88
Nagata S, Pastan I (2009) Removal of B cell epitopes as a practical approach for reducing the immunogenicity of foreign protein-based therapeutics. Adv Drug Deliv Rev 61(11):977–985
Isaacs JD, Waldmann H (1994) Helplessness as a strategy for avoiding antiglobulin responses to therapeutic monoclonal antibodies. Ther Immunol 1(6):303–312
Gilliland LK et al (1999) Elimination of the immunogenicity of therapeutic antibodies. J Immunol 162(6):3663–3671
Waldmann HF, Gillilkand MK, Graca L (2008) Therapeutic antibodies. Patent US 7,465,790 B2
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Waldmann, H. (2019). Human Monoclonal Antibodies: The Benefits of Humanization. In: Steinitz, M. (eds) Human Monoclonal Antibodies. Methods in Molecular Biology, vol 1904. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-8958-4_1
Download citation
DOI: https://doi.org/10.1007/978-1-4939-8958-4_1
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-8957-7
Online ISBN: 978-1-4939-8958-4
eBook Packages: Springer Protocols